Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Pegylated recombinant human factor IX

EU orphan designation number: EU/3/09/640   
Active ingredient: Pegylated recombinant human factor IX
Indication: Treatment of haemophilia B
Sponsor: Novo Nordisk A/S
Novo Allé, DK-2880 Bagsvaerd, Danmark

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
20/05/2009 Centralised Orphan - Designation EMEA/OD/005/09 (2009)4058 of 15/05/2009